Immuneering Corporation Class A Common Stock
IMRX US45254E1073
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Feinberg Peter O |
6.67 USD |
7,500 Bought |
50,025 USD |
03/10/2025 | 03/10/2025 |
Neufeld Leah R SR OFF |
6.38 USD |
800 Bought |
5,103 USD |
01/10/2025 | 01/10/2025 |
Bookman Michael SR OFF |
6.83 USD |
1,020 Bought |
6,967 USD |
01/10/2025 | 01/10/2025 |
Morales Mallory DIR |
6.39 USD |
300 Bought |
1,917 USD |
01/10/2025 | 01/10/2025 |
Feinberg Peter O |
7.03 USD |
7,500 Bought |
52,730 USD |
30/09/2025 | 30/09/2025 |
Feinberg Peter O |
7.18 USD |
5,000 Bought |
35,900 USD |
29/09/2025 | 29/09/2025 |
Neufeld Leah R SR OFF |
3.57 USD |
700 Bought |
2,499 USD |
02/07/2025 | 02/07/2025 |
Hausman Diana O |
3.60 USD |
2,500 Bought |
8,989 USD |
02/07/2025 | 02/07/2025 |
Neufeld Leah R SR OFF |
3.57 USD |
700 Bought |
2,499 USD |
02/07/2025 | 02/07/2025 |
Zeskind Benjamin J. CEO |
3.53 USD |
7,015 Bought |
24,792 USD |
01/07/2025 | 02/07/2025 |